Form 4: Oncology Institute Director Brad Hively Acquires 44,000 Shares of Restricted Stock

Director Brad Hively of Oncology Institute, Inc. acquired 44,000 shares of restricted stock units, which will vest at the 2025 annual shareholder meeting.

Summary

• Brad Hively, a director at Oncology Institute, Inc., acquired 44,000 shares of common stock on November 22, 2024.
• These shares were granted as restricted stock units.
• The restricted stock units will vest in full at the company's 2025 annual shareholder meeting.
• Vesting is contingent upon Mr. Hively's continued service with the company through the vesting date.
• Following this transaction, Mr. Hively's total beneficial ownership of common stock is 720,203 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction of stock-based compensation for a director, which is generally viewed positively as it aligns interests. There are no negative implications or surprises.

Positives

• The acquisition of restricted stock units by a director aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The restricted stock units will vest at the 2025 annual shareholder meeting, subject to continued service.

Industry Context

This type of stock grant is a common practice for aligning the interests of directors with the long-term performance of the company, particularly in the biotech and healthcare sectors.

Comparison to Industry Standards

• Stock-based compensation, including restricted stock units, is a standard practice for directors and executives in publicly traded companies, especially in the biotechnology and healthcare industries.
• Companies like Amgen, Gilead Sciences, and Regeneron often use similar equity-based compensation to incentivize their leadership teams.
• The vesting schedule tied to the annual shareholder meeting is also a common practice to ensure long-term commitment.

Stakeholder Impact

• The stock acquisition aligns the director's interests with those of shareholders, potentially leading to better long-term performance.
• The vesting schedule encourages continued service from the director, which can benefit the company and its stakeholders.

Next Steps

• The restricted stock units will vest at the 2025 annual shareholder meeting, contingent on continued service.

Key Dates

Keywords

restricted stock units, beneficial ownership, director, stock acquisition, vesting, Oncology Institute, TOI